trial · primary record
Hyperpolarized Pyruvate (13C)
Glioblastoma
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 17 |
| Primary completion | 2025-09-30 |
| Primary endpoint | Number of Treatment Emergent Adverse Events (AEs) |
| Registry ID | NCT04019002 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:18.151Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04019002
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.